A systematic review and meta-analysis by Su et al., including 15 clinical trials with 9099 patients, demonstrated that both the anti-CTLA-4 mAbs as monotherapy and the combination of nivolumab with ipilimumab increased the risk of amylase or lipase elevation compared to chemotherapy or placebo, but such regimens did not significantly increase the risk of pancreatitis compared to controls. Here, CTLA4 is linked to pancreatitis.